3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Neoplasms
2
Myocardial Reperfusion Injury
2
Cardiotoxicity
2
Vomiting
1
Uveal Melanoma
1
Thrombosis
1
Substance Withdrawal Syndrome
1
Retinal Diseases
1
Reperfusion Injury
1
Pain, Postoperative
1
Opioid-Related Disorders
1
Nausea
1
Melanoma
1
Macular Degeneration
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Choroid Diseases
1
Breast Neoplasms
1
Interventions
Rituximab
295
Cyclophosphamide
240
Peripheral Blood Stem Cell Transplantation
114
fludarabine phosphate
110
Filgrastim
93
Etoposide
85
Radiotherapy
81
Lenalidomide
79
Vincristine
78
Prednisone
77
Mycophenolic Acid
66
Doxorubicin
61
Cyclosporine
59
Whole-Body Irradiation
58
Bendamustine Hydrochloride
58
Melphalan
57
Tacrolimus
53
Busulfan
51
fludarabine
50
Cytarabine
48
obinutuzumab
46
Methotrexate
45
Antilymphocyte Serum
43
Bortezomib
42
Methylprednisolone
37
Carmustine
37
sargramostim
36
ibritumomab tiuxetan
32
ibrutinib
30
Dexamethasone
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lymphoma, Follicular
×
salicylhydroxamic acid
×
Clear all
NCT04850664
2021-08-06
CBOT-OUD
Evon Medics LLC
Phase 2
Unknown
190 enrolled